Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

NTRK Gene Fusions in NSCLC

August 17th 2020

Future Directions for ROS1 rearranged mNSCLC

August 17th 2020

ALKA-372-001, STARTRK-1, and STARTRK-2 Trials

August 17th 2020

Current Management of ROS1 rearranged NSCLC

August 17th 2020

ROS1 Rearrangements in mNSCLC

August 17th 2020

Molecular Testing for NSCLC

August 17th 2020

Overview of Rare Driver Alterations in NSCLC

August 17th 2020

Chasing a Cure in Lung Cancer: Kris Urges Pushing Forward in COVID-19 Era

August 16th 2020

In an interview with OncLive, Mark G. Kris, MD discusses how the treatment of patients with metastatic lung cancer today bears scant resemblance to what it was when he entered the field 4 decades ago.

Experts Debate the Significance of ADAURA Data With Adjuvant Osimertinib in EGFR+ NSCLC

August 14th 2020

The phase 3 ADAURA trial continues to generate a lot conversation, debate, and excitement in the lung cancer community after results showed that adjuvant osimertinib showed a statistically significant improvement in disease-free survival in patients with stage IB-IIIA EGFR-positive non–small cell lung cancer, making it the first agent to do so in the space.

Sequential Afatinib and Osimertinib Shows Continued OS Benefit in EGFR+ NSCLC

August 10th 2020

Treatment with afatinib followed by osimertinib resulted in a median overall survival benefit of almost 4 years in US patients with EGFR T790M–positive non–small cell lung cancer in the real-world setting.

ASCO 2020 Data Drive New Discussions in NSCLC

August 10th 2020

In a special OncLive video program, The Board, Joshua M. Bauml, MD, led a discussion regarding key abstracts that were presented during the 2020 ASCO Virtual Scientific Program in non–small cell lung cancer .

Optimizing Testing Strategies in Non–Small Cell Lung Cancer

August 10th 2020

NTRK Fusions in Non–Small Cell Lung Cancer

August 10th 2020

MET Exon 14 Mutations in Non–Small Cell Lung Cancer

August 10th 2020

RET Fusions in Non–Small Cell Lung Cancer

August 10th 2020

ROS1-Rearranged Non–Small Cell Lung Cancer

August 10th 2020

Rebiopsy at Progression of ALK-Rearranged NSCLC

August 10th 2020

Treating ALK-Rearranged Non–Small Cell Lung Cancer

August 10th 2020

Trials in ALK-Rearranged Non–Small Cell Lung Cancer

August 10th 2020

KRAS Testing in Non¬–Small Cell Lung Cancer

August 10th 2020